Clinical trial
A Phase I Study to Evaluate the Safety, Tolerability and Immunogenicity of a Therapeutic HIV Vaccine Composed of Autologous Dendritic Cells Loaded With Autologous Inactivated Whole Virus or Conserved Peptides in ART-treated HIV-infected Adults
NCT03758625 is registered in ClinicalTrials.gov with Sharon Riddler as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I Study to Evaluate the Safety, Tolerability and Immunogenicity of a Therapeutic HIV Vaccine Composed of Autologous Dendritic Cells Loaded With Autologous Inactivated Whole Virus or Conserved Peptides in ART-treated HIV-infected Adults
- Lead sponsor
- Sharon Riddler
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- January 2, 2019
- Completion date
- February 19, 2025
- Enrollment
- 40 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.